The effect of multi-ingredient intra- versus extra-cellular buffering supplementation combined with branched-chain amino acids and creatine on exercise-induced ammonia blood concentration and aerobic capacity in taekwondo athletes

Abstract

Background

This study aimed to investigate the effect of multi-ingredient intra- (BA) versus extra- (ALK) cellular buffering factor supplementation, combined with the customary intake of branched-chain amino acids (BCAA) and creatine malate (TCM), on body composition, exercise variables, and biochemical and hematological parameters in 9 elite taekwondo athletes.

Methods

Eight-week randomized double-blind crossover BA (5.0 g·day⁻¹ of β-alanine) versus ALK (0.07 g·kg_FFM⁻¹·day⁻¹ of sodium bicarbonate) supplementation combined with BCAA (0.2 g·kg_FFM⁻¹·day⁻¹) and TCM (0.05 g·kg_FFM⁻¹·day⁻¹) during a standard 8-week taekwondo training period was implemented. In the course of the experiment, body composition (dual X-ray absorptiometry), aerobic capacity (ergospirometric measurements during an incremental treadmill test until exhaustion), and exercise blood biomarkers concentrations were measured. Data were analyzed using repeated measures within-between interaction analysis of variance with the inclusion of experimental supplementation order.

Results

The maximum post-exercise blood ammonia concentration decreased in both groups after supplementation (from 80.3 ± 10.6 to 72.4 ± 10.2 µmol∙L⁻¹, p = 0.013 in BA; from 81.4 ± 8.7 to 74.2 ± 8.9 µmol∙L⁻¹, p = 0.027 in ALK), indicating reduced exercise-related adenosine triphosphate degradation. However, no differences were found in body composition, aerobic capacity, blood lactate concentration, and hematological parameters after neither BA (combined with BCAA and TCM) nor ALK (combined with BCAA and TCM) supplementation.

Conclusions

In highly trained taekwondo athletes, neither extra- nor intracellular buffering enhancement resulting from BA and ALK supplementation, combined with BCAA and TCM treatment, affects body mass and composition, maximum oxygen uptake, and hematological indices, even though certain advantageous metabolic adaptations can be observed.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12970-021-00451-3.

Background

Muscle acidosis, contributing to peripheral and central fatigue, is a crucial problem in sports practice. Experiments at the cellular and molecular level showed that decreased pH and elevated inorganic phosphate negatively affect the force-power curve produced by twitching muscle fibers, their maximum shortening velocity, and motility speed [1]. The exercise-induced acid-base imbalance is a substantial challenge for elite athletes [2–4]. These and other fatigue-related phenomena result in a decrease in physical performance in humans. Acid-base disturbances may be diagnosed with the usage of highly sensitive markers, such as blood ammonia concentration. Ammonia is a waste product of the metabolism of nitrogenous compounds and is considered both a central and peripheral factor behind exercise-induced fatigue. It is produced via the breakdown of branched-chain amino acids (BCAA) in skeletal muscle and the deamination of adenosine monophosphate during exercise [5]. In turn, ammonia metabolism is integrated with the function of kidneys. When acid-base homeostasis is maintained, ammonia metabolism involves both renal and extrarenal pathways [6]. Thus, the implementation of different buffering supplements into athletic training should be supported with the simultaneous analysis of markers such as ammonia.

Many supplementation protocols are often isolated from ergogenic aids that athletes customarily implement. Consequently, they do not reflect the features of competitive sport, omitting additive (synergistic or counteractive) effects of combined use of different supplements, repeated use of supplements, or individual responsiveness [7]. Sports practice observations and previous studies on the efficacy of the use of supplements indicate that BCAA, creatine (CR), beta-alanine (βA), and alkaline agents such as sodium bicarbonate (SB) may be considered as ergogenic support in combat sports [8–11]. BCAAs, especially leucine, have been reported to be responsible for protein synthesis stimulation and/or promoting the anti-catabolic effect [12, 13].

CR is commonly used to increase phosphocreatine (PCr) concentration [14], its resynthesis rate [14], and, consequently, enhance exercise capacity [12]. Moreover, CR supplementation supports the training-induced increases in lean body mass [14], strength [14], and performance in short-duration maximal-intensity exercise [14], which is particularly important in speed-power sports [12, 14]. Nowadays, the most clinically effective and extensively studied form of CR, in terms of performance improvements, is creatine monohydrate [12]. Nevertheless, creatine malate (TCM) seems to be more popular among combat sports athletes, based on the belief about lower water retention in comparison to creatine monohydrate. Although this opinion is widespread in the sports community, there is no conclusive scientific evidence to support it.

βA is a non-essential amino acid that serves as an intracellular buffer [15–18] in muscles, counteracting exercise-induced homeostasis disturbances [12]. It can reduce neuromuscular fatigue, improve performance in exercise bouts lasting up to 4 min, increase the possible number of repetitions or training volume, and indirectly affect lean body mass [12]. βA is a rate-limiting precursor in the synthesis of β-Alanyl-L-histidine (carnosine) [19]. The increases in intramuscular carnosine can attenuate acidosis and fatigue [19]. Its main role in muscles is to attenuate exercise-induced reductions in pH [19].

SB is a primary extra-cellular buffer [15, 20–22] of the efflux of H⁺ ions from contracting muscles to the blood that decreases acidification during high-intensity exercise. It also reduces fatigue during and after anaerobic exercise [12, 23]. SB supplementation results in blood alkalosis, leading to increased efflux of H⁺ and lactate from muscles [24]. Metabolic alkalosis, caused by elevated HCO₃⁻ concentration, upregulates the activity of the glycogenolysis, thus may boost the utilization of muscle glycogen stores during exercise [24, 25]. SB supplementation improves speed, muscle power, and performance in speed-power sports [12, 25].

There is still a need for research on the simultaneous use of different ergogenic supplements (like BCAA and CR) and their combined effect with an additional component influencing the buffering potential on exercise adaptation and performance among competitive professional athletes. To our knowledge, combined supplementation protocols were only used in a scarce number of studies including elite taekwondo athletes [9, 26]. Thus, this study aimed to find out whether multi-ingredient intra- (BA) or multi-ingredient extra- (ALK) cellular buffering treatment in combination with customary BCAA and TCM supplementation has a noticeable effect on body composition, aerobic capacity, respiratory indices, and blood exercise-related and hematological biomarkers in highly trained taekwondo athletes. According to our previous observations [8], we hypothesized that several weeks of combined intra- (BA) cellular buffering agent, BCAA, and TCM supplementation would more effectively support exercise adaptation as evaluated through blood ammonia concentration and aerobic capacity than combined extra- (ALK) cellular buffering agent, BCAA and TCM treatment.

Methods

Participants

Twelve taekwondo athletes were initially enrolled in this study. Eventually, 9 participants (5 male and 4 female) completed the entire study protocol and were included in analyses. The participants were members of the Polish national team meeting specific criteria, i.e. highest level of training status, physical capacity, performance, and technical skills. All of the participants were black belt holders and medalists in ranked competitions (international open tournaments, Universiade, European, and world championships). One athlete took part in the Olympic Games. The inclusion criteria were age from 18 to 35 years, good health, a valid medical certificate confirming the ability to compete and practice sports, and at least 5 years of professional taekwondo training experience. The gender-related impact on the cross-over design of the study was considered negligible. Exclusion criteria were: current smoking or illicit drug use, alcohol consumption greater than 1–2 drinks/week, and dietary supplements beyond those recommended within this study. For females, additional exclusion criteria were being pregnant or planning to become pregnant during the study. Basic training characteristics were also monitored before and during the whole study protocol (initial period, first treatment period, washout, and second treatment period; Table S1). All athletes maintained a high-intensity exercise regime characteristic of taekwondo training and combat during the whole treatment and washout periods. Importantly, each treatment period was preceded by a similar standard training period. Furthermore, all athletes declared that they did not introduce any changes in their lifestyles, especially nutrition, and that they did not use any medications and supplements with potential ergogenic effects other than those supplied by the authors of this study. Dietary records were being performed for two days every second week (current quotation) to ensure that the athletes had not changed their dietary habits during the whole supplementation period. The team member responsible for the diet analysis randomly informed the subjects about the need to start recording their two-day menus. Nutritional data was collected using notes on mobile phones and taking pictures of the meals consumed, which were then sent to the person analyzing the data. Dietary assessment was carried out using the Dietetyk-2 (Jumar, Poznań, Poland) software package following the previously described procedures used in our studies, both including supplementation and nutritional interventions, and weight management [8, 27–29]. The national team coaches enabled the confirmation of the required inclusion criteria declared by the participants. They also supported the control of training and supplementation compliance by monitoring the empty supplement containers, athletes’ diaries, and periodic personal observations of supplementation use by athletes. The project was approved by the Ethics Committee at the Poznan University of Medical Sciences (decision No. 143/15 of 5 February 2015) and was performed according to the ethical standards laid down in the Declaration of Helsinki. Each subject was informed of the testing procedure, purpose, and risks and submitted her/his written consent to participate. The study had been conducted for 1 year, from December 2015 to December 2016. The study complies with the CONSORT Statement for randomized trials as shown in Fig. 1.

Fig. 1.

 A flow chart of the study design. Abbreviations: ALK multi-ingredient extra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; BA multi-ingredient intra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; DXA Dual X-ray Absorptiometry; Pre-EX pre-exercise values; T₁-T₄ the order of laboratory visits and tests (form 1st to 4th visit)

Experimental Design

Supplementation

The effect of supplementation was assessed in a randomized crossover double-blind trial. The primary outcomes were changes in total blood ammonia concentration (NH₃), a specific marker of training adaptation, and aerobic capacity as assessed during an incremental treadmill test until exhaustion. In our previous similar study [8], we assessed the same effects in two extreme cases of exercise performance in highly-trained sprinters vs. endurance athletes. In this study, it was particularly essential to assess the effect of similar supplementation protocol in disciplines with mixed energetics. Of twelve participants, 1 male and 2 females did not complete the study either due to their refusal to participate or resignation without explanation (Fig. 1). After qualifying for the experiment, the athletes were subjected to a randomization procedure and assigned either to the group receiving (i) BA (Beta-Alanine Carno Rush Mega Tabs®, BCAA Mega Caps®, TCM Mega Caps®, and placebo (maltodextrin, PLA) instead of Alkagen™) or (ii) ALK (Alkagen™, BCAA Mega Caps®, TCM Mega Caps®, and PLA instead of Beta-Alanine Carno Rush Mega Tabs®) preparations. The random allocation sequence and assigning participants to supplementation with preparations with specific codes was performed by an impartial scientist who was not a member of the research team. The experimental procedure included an 8-week BA and ALK supplementation. After this period, an 8-week washout period was introduced. The next step was a crossover exchange of the preparations. The 8-week washout and 8-week supplementation periods were established, similar to other studies [30, 31].

Detailed supplementation characteristics are presented in Table 1. During each series of supplementation, all athletes were given the equivalent quantitative doses of about 0.2 g·kg_FFM^− 1 BCAA (11.0 ± 2.2 g·day^− 1 BCAA; BCAA Mega Caps®; 1100 mg·cap^− 1) and about 0.05 g·kg_FFM^− 1 creatine malate (2.8 ± 0.6 g·day^− 1 TCM; TCM Mega Caps®; 1100 mg·cap^− 1). In the BA group, the following preparations were also administered depending on the study phase: 5 capsules of Beta-Alanine Carno Rush Mega Tabs® (containing βA (1000 mg·cap^− 1), sodium citrate (150 mg·cap^− 1), L-histidine HCl (500 mg·cap^− 1), and vitamin B₆ (0.35 mg·cap^− 1)), and PLA (maltodextrin) imitating Alkagen™ alkalizing formulation; the specified doses indicated in Table 1. Concurrently, in the ALK group, the following preparations were administered: about 0.2 g·kg_FFM^− 1 Alkagen™ (11.0 ± 2.2 g·day^− 1 ALK) alkalizing preparation (containing SB (375 mg·cap^− 1), potassium bicarbonate (375 mg·cap^− 1), calcium phosphate (150 mg·cap^− 1), potassium citrate (125 mg·cap^− 1), magnesium citrate (125 mg·cap^− 1), calcium citrate (90 mg·cap^− 1), magnesium oxide (30 mg·cap^− 1), zinc (0.375 mg·cap^− 1)), and a PLA (maltodextrin instead of a Beta-Alanine Carno Rush Mega Tabs); the specified doses indicated in Table 1. The number of capsules (Alkagen, BCAA, TCM) was adjusted to match the prescribed dose in g·kg_FFM^− 1 as close as possible. The preparations were administered in 4 split doses. If one training session a day was foreseen, the split doses were administered at the following times: upon awakening, 60 min before the training session, immediately after the training session, and before sleep. If two training sessions a day were scheduled the times were as follows: upon awakening, 60 min before each training session, and before sleep.

Table 1.

Detailed supplementation characteristics of the examined athletes

BA			ALK
Ingredient	Total daily doses		Ingredient	Total daily doses
	Individual dose	Whole group (g·day− 1)		Individual dose	Whole group (g·day− 1)
		Mean ± SD			Mean ± SD
BCAA	0.20 g·kgFFM−1	11.0 ± 2.2	BCAA	0.2 g·kgFFM−1	11.0 ± 2.2
TCM	0.05 g·kgFFM−1	2.8 ± 0.6	TCM	0.05 g·kgFFM−1	2.8 ± 0.6
Βeta-alanine	5.0 g	5.0	Sodium bicarbonate	0.07 g·kgFFM−1	3.9 ± 0.7
Sodium citrate	0.75 g	0.75	Potassium bicarbonate	0.07 g·kgFFM−1	3.9 ± 0.7
L-histidine HCl	2.5 g	2.5	Calcium phosphate	0.03 g·kgFFM−1	1.7 ± 0.3
Vitamin B6	1.75 mg	0.00175	Potassium citrate	0.025 g·kgFFM−1	1.4 ± 0.3
			Magnesium citrate	0.025 g·kgFFM−1	1.4 ± 0.3
			Calcium citrate	0.018 g·kgFFM−1	1.0 ± 0.2
			Magnesium oxide	0.006 g·kgFFM−1	0.3 ± 0.1

Abbreviations: ALK multi-ingredient extra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; BA multi-ingredient intra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; BCAA branched-chain amino acids; FFM fat-free mass; SD standard deviation; TCM creatine malate

All products, including PLA preparations, were prepared by one manufacturer (Olimp Laboratories, Dębica, Poland). Preparations were coded, making it impossible to identify and assign the same preparation twice to the same subject.

Laboratory Visits

The study protocol included four visits to the Human Movement Laboratory “_LA_BTHLETICS” of the Department of Athletics, Strength and Conditioning at the Poznan University of Physical Education, Poznań, Poland (Fig. 1). Subjects were instructed not to participate in any high-intensity or long-duration training sessions at least 24 h before testing. All measurements were performed in the morning, 3 h after a light breakfast (no coffee or tea). At the start, subjects underwent body composition analysis. Afterward, an incremental treadmill test until volitional exhaustion was performed. During all measurements, the ambient temperature remained at 20‒21^oC. The subjects were familiar with the tests and procedures used as they had participated in some previous research projects.

Anthropometry and Body Composition

Body mass (kg) and height (cm) were measured using a digital stadiometer (SECA 285, Hamburg, Germany). Body mass index (BMI) was calculated by dividing body mass by height squared. The Dual X-ray Absorptiometry (DXA) method, utilizing the Lunar Prodigy Pro device (GE Healthcare, Madison, Wisconsin, USA) and enCORE v. 16 SP1 software, was used for body composition assessment. During the examination, subjects only wore their undergarments, without jewelry and metal objects to minimize measurement error. The measurements were carried out according to the standardized scanning protocol as recommended by Nana et al. [32].

Cardiorespiratory Test

An exercise test on the Pulsar mechanical treadmill (H/P Cosmos Sports & Medical GmbH, Nussdorf-Traunstein, Germany) was performed to determine maximal oxygen uptake (V̇O_2max). The initial speed was set at 4 km·h⁻¹ and increased after 3 min to 8 km·h⁻¹. After that point, treadmill speed progressively increased by 2 km·h⁻¹ every 3 min until volitional exhaustion. After the speed of 10 km·h⁻¹ was reached, venous blood samples were drawn at the end of each 3-min stage during pauses of up to 20 s. Minute ventilation (V̇E), oxygen uptake (V̇O₂), carbon dioxide production, respiratory exchange ratio (RER), and other respiratory parameters were measured (breath by breath) by the Metamax 3B R2 ergospirometer and analyzed using MetasoftStudio v. 5.1.0 Software (Cortex Biophysik, Leipzig, Germany). Heart rate (HR) was monitored using the Bluetooth Smart H6 heart rate monitor (Polar Electro Oy, Kempele, Finland). The V̇O₂max and corresponding exercise variables were considered to be reached when at least three of the following criteria were met: (1) a plateau in V̇O₂ despite an increase in speed and minute ventilation; (2) blood lactate concentration at exhaustion ≥ 9 mmol∙L⁻¹, (3) respiratory exchange ratio ≥ 1.10, and (4) heart rate ≥ 95 % of maximum (based on previous measurements) [33]. Also, V̇O₂, V̇E, HR, and RER at the ventilatory threshold were determined based on the ventilatory equivalents and partial pressures of oxygen and carbon dioxide.

Blood Sampling

A catheter (BD Venflon Pro 1.3 × 32 mm, Helsingborg, Sweden) patent with isotonic saline (0.9 % NaCl) was placed in the antecubital vein. Blood samples were taken into two monovettes (S-Monovette 2.7 ml KE, Sarstedt, Nümbrecht, Germany), one with a lithium anticoagulant (heparin) for lactate and NH₃ assay and another containing the EDTA anticoagulant for hematological measurements.

Lactate and Ammonia

To determine lactate concentration (LA), 20 µl of whole blood was placed into a capillary and placed in the Biosen C-line device (EKF diagnostic GmbH, Barleben, Germany). To determine total blood ammonia concentration, the PocketChem BA PA-4140 device (Arkray, Kyoto, Japan) was used with measuring range and accuracy (CV) of 8‒285 µmol·L⁻¹ and 2.3 %, respectively. Immediately after drawing blood, a sample of 20 µl was placed on the test strip (Ammonia Test Kit II, Arkay, Kyoto, Japan) using a pipette. Ammonium ions in the sample were converted into the gaseous form that reacted with an indicator layer to change its color. The light of a wavelength of 635 nm, reflected by the indicator layer, was used to determine the level of color indicative of ammonia concentration.

Hematological Measurements

Ten µl of blood were analyzed in the automated Mythic®18 analyzer (Orphée, Geneva, Switzerland) to determine concentrations of white blood cells (WBC), lymphocytes (Lym), monocytes (Mon), granulocyte (Gra), red blood cells (RBC), hemoglobin (Hb), and hematocrit (Ht).

Statistical analysis

Stratified randomization was performed with fat-free mass (FFM) being a prognostic variable as described previously [8, 30, 34, 35]. The results are presented as means ± standard deviation (and 95 % confidence intervals). The normality of data was tested using the Shapiro-Wilk test. If the distribution was not normal, the Box-Cox transformation was applied. Data were analyzed using repeated measures within-between interaction analysis of variance (ANOVA) with the inclusion of experimental supplementation order (BA first or ALK first), which allowed for the elimination of the potential carryover effect. The analysis also included factors independent of time: treatment (BA/ALK) x period (Before/After). Post hoc analysis was done using Bonferroni correction. If the sphericity assumption was violated, the Greenhouse-Geisser and the Huynh-Feldt corrections were performed. The sample size was estimated a priori, assuming that the effect size of supplementation type on ammonia blood concentration was 0.42 (partial eta-squared) as shown in our previous study [8]. Using an α-level of 0.05, a power (1 – β) of 0.80, it was calculated that at least 8 participants in each supplementation group would be needed to detect a significant change or differences in the variables analyzed (G*Power; Heinrich-Heine-Universität, Düsseldorf, Germany). To compare the anthropometric traits, training history, and diet characteristics, independent samples t-tests or Mann–Whitney U tests were performed, depending on data distribution (parametric or nonparametric, respectively). Statistical significance was set at p < 0.05 and data were analyzed using the Statistica 12 software package (StatSoft Inc., Tulsa, OK, USA).

Results

Baseline characteristics

The baseline characteristics of the studied taekwondo athletes are presented in Table 2. After randomization, there were no differences between the groups.

Table 2.

Baseline anthropometric, training, and diet characteristics of the examined athletes

		BA→ALK group			ALK→BA group			BA→ALK vs. ALK→BA group
		Mean	±	SD	Mean	±	SD	p-value
N		5			4			-
Age	(years)	21	±	3	19	±	3	0.27
Body height	(cm)	181	±	6	179	±	10	0.60
Body mass	(kg)	68.1	±	1.2	70.2	±	14.5	0.75
Fat mass	(kg)	13.8	±	5.6	14.5	±	3.6	1.00
Fat-free mass	(kg)	54.2	±	5.5	56.2	±	16.9	0.81
V̇O2max	(L·min−1)	3.65	±	0.67	3.68	±	1.09	0.95
Training experience	(years)	8	±	1	9	±	3	0.52
Energy intake	(kcal·day−1)	2343	±	492	2796	±	472	0.20
	(kcal·kg−1)	35.1	±	7.3	41.6	±	14.0	0.39
Protein intake	(g·day−1)	109	±	19	111	±	15	0.86
	(g·kg−1)	1.6	±	0.3	1.6	±	0.5	0.71
	(% of energy)	18.9	±	3.1	16.2	±	2.9	0.21
Fat intake	(g·day−1)	71	±	27	106	±	42	0.17
	(g·kg−1)	1.1	±	0.4	1.6	±	0.7	0.21
	(% of energy)	26.6	±	6.1	33.1	±	10.6	0.28
Carbohydrate intake	(g·day−1)	338	±	60	379	±	57	0.33
	(g·kg−1)	5.1	±	0.9	5.7	±	2.0	0.56
	(% of energy)	58.1	±	3.4	55.0	±	9.1	0.51

Values are expressed as means ± standard deviation (SD). Abbreviations: ALK multi-ingredient extra-cellular buffering supplement; ALK→BA group the order of implementing the supplementation, 1st ALK, 2nd BA after wash-out; BA multi-ingredient intra-cellular buffering supplement; BA→ALK group the order of implementing the supplementation, 1st BA, 2nd ALK after wash-out; V̇O_2max maximal oxygen uptake

Body composition

No significant body mass and composition differences (p > 0.05) were revealed between BA and ALK groups and before versus after supplementation (Table 3).

Table 3.

Body mass and composition in taekwondo athletes before and after supplementation

			BA						ALK
			Mean	±	SD	95% CI			Mean	±	SD	95% CI
Body mass	(kg)	Before	68.0	±	9.9	60.4	-	75.6	67.0	±	9.0	60.1	-	73.9
		After	69.1	±	9.3	62.0	-	76.3	69.0	±	8.7	62.3	-	75.6
BMI	(kg∙m−2)	Before	21.1	±	2.3	19.3	-	22.8	20.7	±	2.1	19.1	-	22.3
		After	21.4	±	2.1	19.8	-	23.1	21.4	±	2.1	19.7	-	23.0
Total Fat Mass	(kg)	Before	12.6	±	4.0	9.5	-	15.8	12.6	±	3.9	9.6	-	15.6
		After	13.8	±	3.9	10.8	-	16.8	14.1	±	4.6	10.5	-	17.6
Total Fat-Free Mass	(kg)	Before	55.5	±	12.2	46.1	-	64.8	54.9	±	11.2	46.3	-	63.5
		After	55.8	±	11.2	47.2	-	64.4	55.4	±	11.4	46.6	-	64.1

Data are the means ± standard deviation (SD) and 95% confidence intervals (CI). Abbreviations: After after supplementation; ALK multi-ingredient extra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; BA multi-ingredient intra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; Before before supplementation; BMI body mass index.

Pre-exercise and exercise cardiorespiratory indices

No significant differences in aerobic capacity indices (p > 0.05) were found between/within groups and before/after supplementation (Table 4).

Table 4.

Pre-exercise and exercise cardiorespiratory variables in taekwondo athletes before and after supplementation

			BA						ALK
			Mean	±	SD	95% CI			Mean	±	SD	95% CI
V̇EPre-EX	(L∙min−1)	Before	14.0	±	2.5	12.1	-	16.0	14.1	±	2.0	12.6	-	15.7
		After	13.9	±	2.8	11.7	-	16.0	15.9	±	2.8	13.7	-	18.0
HRPre-EX	(bpm)	Before	83	±	13	73	-	93	80	±	13	70	-	90
		After	83	±	12	73	-	92	85	±	13	75	-	95
V̇O2Pre-EX	(L∙min−1)	Before	0.49	±	0.09	0.42	-	0.56	0.47	±	0.07	0.42	-	0.53
		After	0.48	±	0.07	0.43	-	0.54	0.56	±	0.11	0.47	-	0.65
RERPre-EX		Before	0.79	±	0.04	0.76	-	0.83	0.83	±	0.05	0.79	-	0.87
		After	0.81	±	0.08	0.75	-	0.88	0.81	±	0.08	0.75	-	0.86
V̇EVT	(L∙min−1)	Before	68.7	±	20.5	53.0	-	84.5	67.1	±	19.7	52.0	-	82.3
		After	65.9	±	17.5	52.4	-	79.4	68.0	±	17.8	54.2	-	81.7
HRVT	(bpm)	Before	161	±	15	150	-	173	158	±	15	147	-	170
		After	159	±	15	148	-	171	161	±	18	147	-	174
V̇O2VT	(L∙min−1)	Before	2.55	±	0.68	2.03	-	3.08	2.59	±	0.70	2.05	-	3.13
		After	2.56	±	0.58	2.11	-	3.01	2.64	±	0.59	2.18	-	3.09
RERVT		Before	0.90	±	0.05	0.86	-	0.94	0.91	±	0.04	0.88	-	0.95
		After	0.89	±	0.08	0.83	-	0.96	0.89	±	0.05	0.85	-	0.93
V̇Emax	(L∙min−1)	Before	129	±	30	106	-	152	129	±	31	106	-	153
		After	127	±	31	104	-	151	129	±	30	106	-	152
HRmax	(bpm)	Before	189	±	14	178	-	200	192	±	11	183	-	200
		After	193	±	12	184	-	202	193	±	10	186	-	201
V̇O2max	(L∙min−1)	Before	3.64	±	0.84	2.99	-	4.29	3.54	±	0.77	2.95	-	4.14
		After	3.66	±	0.82	3.03	-	4.29	3.68	±	0.86	3.02	-	4.33
RERmax		Before	1.10	±	0.05	1.06	-	1.13	1.10	±	0.03	1.07	-	1.13
		After	1.06	±	0.07	1.01	-	1.11	1.09	±	0.06	1.05	-	1.14

Data are the means ± standard deviation (SD) and 95% confidence intervals (CI). Abbreviations: After after supplementation; ALK multi-ingredient extra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; BA multi-ingredient intra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; Before before supplementation; HR heart rate; max maximum values; Pre-EX pre-exercise values; RER respiratory exchange ratio; V̇E minute ventilation; V̇O₂ oxygen uptake; VT ventilatory threshold. No significant differences reported (p > 0.05).

Blood biomarkers

The concentration of two blood biomarkers and hematological parameters is given in Table 5; Fig. 2. There were no significant differences in BA and ALK groups before and after supplements administration, except NH₃ concentration. In the BA group, pre-exercise (NH_3Pre−EX) and maximal post-exercise (NH_3max) ammonia concentration decreased significantly after supplementation protocols. In the ALK group, NH_3max concentration decreased significantly after the supplementation period (Fig. 2).

Table 5.

The level of exercise blood biomarkers and hematological parameters in taekwondo athletes before and after supplementation (pre-exercise, maximum, and recovery values)

			BA						ALK
			Mean	±	SD	95% CI			Mean	±	SD	95% CI
LAPre-EX	(mmol∙L−1)	Before	1.07	±	0.19	0.92	-	1.21	1.18	±	0.27	0.97	-	1.39
		After	1.13	±	0.26	0.93	-	1.33	1.10	±	0.30	0.88	-	1.33
LAmax	(mmol∙L−1)	Before	10.9	±	1.6	9.7	-	12.1	10.9	±	2.1	9.3	-	12.5
		After	10.2	±	1.4	9.1	-	11.3	10.7	±	1.9	9.2	-	12.2
LAR5	(mmol∙L−1)	Before	10.33	±	1.64	9.07	-	11.59	9.99	±	1.50	8.83	-	11.14
		After	9.57	±	1.65	8.31	-	10.84	9.60	±	1.55	8.41	-	10.79
LAR20	(mmol∙L−1)	Before	6.37	±	1.77	5.01	-	7.73	6.27	±	1.66	4.99	-	7.54
		After	5.80	±	1.44	4.69	-	6.90	5.91	±	1.60	4.68	-	7.14
LAR30	(mmol∙L−1)	Before	4.63	±	1.58	3.42	-	5.85	4.21	±	1.51	3.05	-	5.36
		After	4.13	±	1.19	3.21	-	5.04	3.93	±	1.33	2.91	-	4.96
NH3Pre-EX	(μmol∙L−1)	Before	22.7	±	1.9	21.2	-	24.1	22.6	±	2.3	20.8	-	24.3
		After	20.8	±	1.9*	19.4	-	22.2	21.6	±	2.4	19.7	-	23.4
NH3max	(μmol∙L−1)	Before	80.3	±	10.6	72.2	-	88.5	81.4	±	8.7	74.8	-	88.1
		After	72.4	±	10.2**	64.6	-	80.3	74.2	±	8.9 ***	67.4	-	81.0
NH3R5	(μmol∙L−1)	Before	66.4	±	15.9	54.2	-	78.7	69.2	±	11.4	60.4	-	78.0
		After	61.1	±	17.8	47.4	-	74.8	61.8	±	8.7	55.1	-	68.5
NH3R20	(μmol L−1)	Before	48.2	±	11.5	39.4	-	57.1	48.8	±	6.8	43.6	-	54.0
		After	43.9	±	12.4	34.3	-	53.4	44.4	±	6.3	39.6	-	49.3
NH3R30	(μmol∙L−1)	Before	38.8	±	6.5	33.8	-	43.8	37.8	±	4.4	34.4	-	41.1
		After	34.8	±	8.5	28.2	-	41.3	33.6	±	4.6	30.0	-	37.1
WBCPre-EX	(x109∙L−1)	Before	5.88	±	1.32	4.86	-	6.89	5.76	±	0.98	5.00	-	6.51
		After	5.27	±	0.98	4.51	-	6.02	5.06	±	0.80	4.44	-	5.67
LymPre-EX	(x109∙L−1)	Before	1.74	±	0.24	1.56	-	1.93	1.76	±	0.36	1.48	-	2.03
		After	1.91	±	0.19	1.77	-	2.06	1.86	±	0.40	1.55	-	2.17
MonPre-EX	(x109∙L−1)	Before	0.30	±	0.10	0.22	-	0.38	0.41	±	0.15	0.30	-	0.52
		After	0.38	±	0.15	0.26	-	0.49	0.39	±	0.13	0.29	-	0.49
GraPre-EX	(x109∙L−1)	Before	3.81	±	1.28	2.83	-	4.79	3.60	±	0.79	2.99	-	4.21
		After	2.98	±	0.82	2.35	-	3.60	2.81	±	0.58	2.37	-	3.26
RBCPre-EX	(x1012∙L−1)	Before	4.68	±	0.50	4.29	-	5.06	4.96	±	0.53	4.55	-	5.38
		After	4.60	±	0.39	4.30	-	4.90	4.65	±	0.38	4.36	-	4.95
HbPre-EX	(mmol∙L−1)	Before	8.60	±	0.86	7.94	-	9.27	8.78	±	0.64	8.28	-	9.27
		After	8.47	±	0.84	7.83	-	9.12	8.36	±	0.43	8.03	-	8.69
HtPre-EX	(L∙L−1)	Before	0.40	±	0.04	0.37	-	0.43	0.41	±	0.03	0.39	-	0.44
		After	0.40	±	0.03	0.37	-	0.42	0.39	±	0.02	0.38	-	0.41

Data are mean ± standard deviation (SD) and 95% confidence intervals (CI). *,**,***: significant difference between “Before” and “After” values (* p=0.006, ** p= 0.013, *** p=0.027). Abbreviations: After after supplementation; ALK multi-ingredient extra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; BA multi-ingredient intra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; Before before supplementation; Gra granulocytes; Hb hemoglobin; Ht hematocrit; LA lactate; Lym lymphocytes; Mon monocytes; NH₃ ammonia; Pre-EX pre-exercise values; R post-exercise recovery period (5, 20, 30 = minute of recovery); RBC red blood cells; TCM creatine malate; WBC white blood cells

Fig. 2.

Blood ammonia (NH₃) concentration during the post-exercise recovery before and after supplementation. Data are the means ± standard deviation (SD) and individual results. *,**,***: significant difference between “Before” and “After” values (* p = 0.006, ** p = 0.013, *** p = 0.027). Abbreviations: After after supplementation; ALK multi-ingredient extra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; BA multi-ingredient intra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; Before before supplementation; max maximum value after exercise; Pre-EX pre-exercise values

Discussion

In this study, elite taekwondo athletes were supplemented with BA or ALK combined with BCAA and TCM administration during an 8-week training period (description in Table S1). We did not observe any significant changes in body mass and composition neither in the BA nor ALK group. Despite many studies suggesting the effect of such preparations on respiratory and aerobic capacity, we did not observe any major impact. Also, we did not reveal any significant changes in hematological parameters. As far as exercise blood biomarkers are concerned, the only change we observed was the statistically significant decrease in NH_3max concentration after administration of both BA and ALK supplementation combined with BCAA and TCM.

Supplements and their doses used in this study were chosen after evaluating the available scientific literature and determining the efficacy and safety of these substances [12]. Moreover, elite athletes participating in our study were healthy and particularly in need of taking these supplements, mainly for proper recovery, training adaptation, or avoidance of health consequences.

No significant differences in body mass and composition are in agreement with the findings of Kendrick et al. [36] who revealed that a 10-week resistance training combined with βA did not significantly change body fat percentage. Also, Smith et al. [37] showed no significant changes in body mass, fat mass, and fat percentage, but they reported significant increases in lean body mass in a βA group after high-intensity interval training. A study on highly trained sprinters showed increases in total fat-free mass after βA supplementation (combined with BCAA and TCM) [8]. In contrast, Kern and Robinson [38] showed no significant changes in lean body and fat mass in trained football players and wrestlers supplemented with βA. However, Hoffman et al. [39] reported a greater increase in lean body mass and a decrease in the percentage of body fat after βA and CR supplementation compared to CR alone in strength/power athletes, even though no between-protocol differences in total body and fat mass were observed. It seems that the gain in lean body mass after βA treatment, reported in some studies [37, 39], can be partly explained by minimizing the exercise-induced muscle acidification and is related to the preparedness for increases in training volume and/or improved muscle metabolism. We have not found any studies monitoring body composition changes in response to SB treatment in highly trained athletes. Our study suggests that supplementation of alkaline agents during several weeks does not affect body composition in striking combat sports contestants, specifically taekwondo athletes.

We found no significant differences in cardiorespiratory exercise indices after any of the supplementation protocols. It must be stressed that taekwondo training and combat are characterized by mixed energetics. In simulated taekwondo combats, the contribution of aerobic, anaerobic phosphagen, and glycolytic energy systems is 66 %, 30 %, and 4 %, respectively, with a probable shift towards anaerobic energy sources during real tournaments [40, 41]. Our results are in agreement with the study by Baguet et al. [42] that found no effect on V̇O_2peak after βA supplementation in physically active males. It also seems that high-intensity interval training (HIIT) better supports aerobic capacity gains than moderate-intensity exercise. Although taekwondo training is largely based on specific HIIT, in our opinion the aerobic adaptation changes could not be detectable in elite athletes who took part in our study. Their aerobic capacity was already at a high level (optimal for sports discipline they practice) and it was hard to expect further improvements. Lopes-Silva et al. [43] conducted a simulated combat study on 9 male taekwondo athletes ingesting SB and demonstrated no significant differences in HR and V̇O₂ between the SB group and placebo, either. In the latest crossover study including elite sprinters and endurance athletes, respiratory and aerobic capacity indices also remained unchanged after BA and ALK supplementation [8], which further confirms the results we obtained from the taekwondo athletes.

Unlike competitive athletes, recreationally active people usually noticeably improve their aerobic capacity (peak V̇O₂) if combined supplementation with βA and HIIT is administered [37]. Zoeller et al. [44] measured the effect of supplementation with βA in combination with CR on aerobic exercise performance in 55 men and demonstrated a significant improvement in V̇O_2max and V̇O₂ at the ventilatory threshold with combined supplementation group compared to βA or CR alone. In SB supplementation studies, progressive-dose SB ingestion improved CrossFit-specific performance and delayed ventilatory threshold occurrence [30]. Studies involving recreationally active people also proved the effect of SB supplementation on cardiorespiratory exercise indices [45, 46]. Summarizing these aspects, training status and sports performance level may have a crucial impact on the effect of agents supporting buffer capacity. This effect can be less visible or not visible at all in competitive elite athletes representing a high level of exercise adaptation.

Earlier studies showed significant changes in blood lactate concentration after supplementation with alkaline agents. Artioli et al. [47], Carr et al. [24], and Saunders et al. [48] found that acute SB supplementation (0.3 g·kg⁻¹ before exercise) resulted in higher lactate concentration in experienced judo competitors, resistance-trained males, and recreationally active men, respectively. Other studies including athletes [43, 49] also showed that peak blood lactate concentration increased after acute SB administration (0.3 g·kg⁻¹ before exercise). Likewise, studies on recreationally active people [45, 46, 50] resulted in higher blood lactate concentration compared to placebo. It was suggested that increased blood lactate after SB ingestion was observed in individuals who improved their exercise capacity [48]. SB ingestion increases lactate concentration due to increased efflux of lactate and H⁺ from muscles into the extracellular fluid [43]. It seems that the differences between our observations and other research result from different supplementation protocols (chronic vs. acute supplementation). The available data indicate that acute treatment with a higher dose may be more effective than chronic supply in divided doses [8, 27, 30]. In our study, the doses of SB might have been relatively too low to produce significant effects.

Insignificant changes in lactate concentration in this study could result from the specificity of the progressive treadmill test that diverged from workload during typical taekwondo training sessions or tournament combats. Kern and Robinson [38] showed only minor changes in blood lactate concentrations in the placebo and βA-supplemented groups (small increases in trained football players and small decreases in wrestlers). Kratz et al. [10] found that βA administration in judokas resulted in significant increases in lactate concentration. As mentioned above, this may suggest that, similarly to SB, βA improves the ability to clear or tolerate higher muscle acidification, depending on exercise specificity, allowing athletes to exercise at a higher intensity or over a longer period.

In our study, the only significant change was detected for NH₃ after both BA (pre-exercise and maximum concentrations) and ALK (maximum concentration) supplementation. To our knowledge, this is the first study to demonstrate such an effect on NH₃ concentration in highly trained combat sports athletes. There is relatively little literature data, mainly concerning endurance disciplines, on the connection between ergogenic supplementation and NH₃ concentration in athletes. The decreased maximum post-exercise blood ammonia concentration observed in our study may be metabolically important since previous reports revealed that NH₃ is a sensitive marker of the exercise-induced metabolic response to incremental exercise [51–53]. Hsueh et al. [54] indicated that combined supplementation with BCAA, arginine, and citrulline did not change pre- and post-exercise NH₃ concentration. However, our previous study on the BA treatment combined with BCAA and TCM in international level sprinters and endurance athletes yielded a reverse result [8]. Some studies [55–57] suggest that the use of certain single ergogenic supplements may decrease exercise-induced hyperammonaemia. A smaller NH₃ concentration might hinder the harmful influence of ammonia on protein synthesis and BCAA catabolism, supporting performance, e.g. through the suppression of central fatigue and motor coordination aggravation [51, 58, 59]. Furthermore, a lower post-exercise increase in NH₃ concentration can be related to lower adenosine triphosphate depletion and slower glycolysis and glycogenolysis rate, especially in exercising skeletal muscles [53, 60]. In this current study, the change was statistically significant but its practical relevance may be questionable because no other measure we used supported the potential effect of NH₃ reduction on better exercise economy, lower physiological cost of muscle work, reduced fatigue, or enhanced metabolic adaptation. This issue requires further research.

This study has some limitations. We cannot be sure that the athletes completely adhered to our recommendations. Also, other exercise-derived data than those concerning aerobic adaptation could help to better interpret the results (e.g. high-intensity anaerobic and discipline-specific tests). The duration of exercise in the high-intensity zone during the progressive test was probably too short to reveal more clear-cut changes in the supplementation-induced indices of exercise capacity. Future studies should focus on implementing high-intensity exercise tests. There was also no control/placebo group, however, only elite athletes had been involved in the study and it was not possible to apply a procedure in which athletes would only have to receive a placebo or not be supplemented at all. It is important to underline that it was not possible to conduct controlled studies on these athletes without their customary supplementation. Elite athletes could be only supplemented and tested during the specific period, taking into account long-term training and competition plans. The inclusion of athletes with lower training status would make the results incomparable between the groups. Probably, a larger sample size would give more pronounced results. The numbers of training sessions/hours and workout specificity fluctuated somewhat across the consecutive 8-week periods, however, the volume and intensity remained comparable, as previously described [37]. This, and the cross-over design, minimized the confounding effect of changes in training loads and allowed to isolate the effect of the administered supplementation. However, it should be noted that in our study training loads and some minor factors could not be fully controlled. Even if training loads would be the same across the 24 weeks, the athletes’ training status would gradually change due to physiological adaptation. On the other hand, our study provides insight into the actual effects of supplementation during the real training process, contrary to laboratory studies conducted in ‘artificial’ conditions, not adequate to typical competitive sports participation. As we described in the methods section, all athletes maintained taekwondo-specific high-intensity training before and during the entire study period. Finally, it is important to underline that the doses of the supplements could be not high enough to produce substantial changes in monitored indices. Nevertheless, the strength of our research is the participation of current elite athletes, supplementation during the real training process, group homogeneity, and application of the cross-over design study.

Many coaches and highly trained athletes are convinced that the lack of supplementation negatively affects physical performance and nutritional status. Consequently, combined supplementation is administered as a preventive measure during critical periods of the annual training cycle, i.e. when (i) athletes are loaded with many training units a day/week, (ii) they have very short and often sub-optimal recovery breaks between training sessions, or (iii) covering the high nutritional needs using a standard diet is difficult. Athletes customarily use multiple supplements intending to enhance their performance and enable participation in heavy training cycles. Our research is partly filling in the gap in evidence-based studies on the combined supplementation use among trained athletes, especially on buffering agents and other ergogenic supplements. The future challenge for scientists and medical staff (sports nutritionists, physiologists, and medical doctors) is the elaboration of practical and effective strategies to counteract the negative effects of the exercise-induced acid-base imbalance.

Conclusions

In highly trained taekwondo athletes, both extra- and intracellular buffering enhancement resulting from an 8-week BA and ALK supplementation, respectively, combined with BCAA and TCM treatment, solely resulted in a modest reduction in total blood ammonia concentration at the exercise intensity corresponding to V̇O₂max, however, without significant changes in body mass and composition, aerobic capacity, and hematological indices.

Abbreviations

ALK

Multi-ingredient extra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate

After

After supplementation

BA

Multi-ingredient intra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate

BCAA

Branched-chain amino acids

Before

Before supplementation

BMI

Body mass index

βA

Beta-alanine

CI

Confidence intervals

CR

Creatine

CV

Measurement accuracy

DXA

Dual X-ray Absorptiometry

FFM

Fat-free mass

Gra

Granulocyte

Hb

Hemoglobin

HR

Heart rate

Ht

Hematocrit

LA

Lactate concentration

Lym

Lymphocytes

Mon

Monocytes

NH₃

Total blood ammonia

PCr

Phosphocreatine

PLA

Placebo

Pre-EX

Pre-exercise values

R

Post-exercise recovery period

RBC

Red blood cells

RER

Respiratory exchange ratio

SB

Sodium bicarbonate

SD

Standard deviation

TCM

Creatine malate

V̇E

Minute ventilation

V̇O_2max

Maximal oxygen uptake

V̇O₂

Oxygen uptake

VT

Ventilatory threshold

WBC

White blood cells

Authors’ contributions

Conceptualization, K.D.-M.; methodology, K.D.-M, K.K., and J.Z.; software, K.D.-M, K.K., and J.Z.; validation, K.D.-M, K.K., and J.Z.; formal analysis, K.D.-M, K.K., and J.Z.; investigation, K.D.-M, K.K., and J.Z.; resources, K.D.-M, K.K., and J.Z.; data curation, K.D.-M, and N.G.; writing—original draft preparation, K.D.-M and N.G.; writing—review and editing, K.D.-M, K.K., and J.Z.; visualization, K.D.-M; supervision, K.D.-M, K.K., and J.Z.; project administration, J.Z.; funding acquisition, K.D.-M, K.K., and J.Z. All authors have read and agreed to the published version of the manuscript.

Funding

This study was funded by the Polish Ministry of Science and Higher Education, grant number RSA3 03653.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on request.

Declarations

Ethics approval and consent to participate

The study was approved by the Bioethics Committee at Poznan University of Medical Sciences (Poland) was granted for this study (decision No. 143/15 of 5 February 2015). Following the Declaration of Helsinki, all participants signed informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.